1gzq: Difference between revisions
No edit summary |
No edit summary |
||
Line 2: | Line 2: | ||
<StructureSection load='1gzq' size='340' side='right' caption='[[1gzq]], [[Resolution|resolution]] 2.26Å' scene=''> | <StructureSection load='1gzq' size='340' side='right' caption='[[1gzq]], [[Resolution|resolution]] 2.26Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[1gzq]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/ | <table><tr><td colspan='2'>[[1gzq]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1GZQ OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1GZQ FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=D12:DODECANE'>D12</scene>, <scene name='pdbligand=NO3:NITRATE+ION'>NO3</scene>, <scene name='pdbligand=PII:2-[(HYDROXY{[(2R,3R,5S,6R)-2,3,4,5,6-PENTAHYDROXYCYCLOHEXYL]OXY}PHOSPHORYL)OXY]-1-[(PALMITOYLOXY)METHYL]ETHYL+HEPTADECANOATE'>PII</scene>, <scene name='pdbligand=TWT:DOCOSANE'>TWT</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=D12:DODECANE'>D12</scene>, <scene name='pdbligand=NO3:NITRATE+ION'>NO3</scene>, <scene name='pdbligand=PII:2-[(HYDROXY{[(2R,3R,5S,6R)-2,3,4,5,6-PENTAHYDROXYCYCLOHEXYL]OXY}PHOSPHORYL)OXY]-1-[(PALMITOYLOXY)METHYL]ETHYL+HEPTADECANOATE'>PII</scene>, <scene name='pdbligand=TWT:DOCOSANE'>TWT</scene></td></tr> | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1gzp|1gzp]], [[1a1m|1a1m]], [[1a1n|1a1n]], [[1a1o|1a1o]], [[1a6z|1a6z]], [[1a9b|1a9b]], [[1a9e|1a9e]], [[1agb|1agb]], [[1agc|1agc]], [[1agd|1agd]], [[1age|1age]], [[1agf|1agf]], [[1akj|1akj]], [[1ce6|1ce6]], [[1de4|1de4]], [[1e27|1e27]], [[1e28|1e28]], [[1efx|1efx]], [[1exu|1exu]], [[1hhg|1hhg]], [[1hhh|1hhh]], [[1hhi|1hhi]], [[1hhj|1hhj]], [[1hhk|1hhk]], [[1hla|1hla]], [[1hsa|1hsa]], [[1hsb|1hsb]], [[1i4f|1i4f]], [[1i7r|1i7r]], [[1i7t|1i7t]], [[1i7u|1i7u]], [[1im3|1im3]], [[1im9|1im9]], [[1jf1|1jf1]], [[1jht|1jht]], [[1jnj|1jnj]], [[1qlf|1qlf]], [[1qqd|1qqd]], [[1tmc|1tmc]], [[2clr|2clr]], [[2hla|2hla]], [[3hla|3hla]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1gzp|1gzp]], [[1a1m|1a1m]], [[1a1n|1a1n]], [[1a1o|1a1o]], [[1a6z|1a6z]], [[1a9b|1a9b]], [[1a9e|1a9e]], [[1agb|1agb]], [[1agc|1agc]], [[1agd|1agd]], [[1age|1age]], [[1agf|1agf]], [[1akj|1akj]], [[1ce6|1ce6]], [[1de4|1de4]], [[1e27|1e27]], [[1e28|1e28]], [[1efx|1efx]], [[1exu|1exu]], [[1hhg|1hhg]], [[1hhh|1hhh]], [[1hhi|1hhi]], [[1hhj|1hhj]], [[1hhk|1hhk]], [[1hla|1hla]], [[1hsa|1hsa]], [[1hsb|1hsb]], [[1i4f|1i4f]], [[1i7r|1i7r]], [[1i7t|1i7t]], [[1i7u|1i7u]], [[1im3|1im3]], [[1im9|1im9]], [[1jf1|1jf1]], [[1jht|1jht]], [[1jnj|1jnj]], [[1qlf|1qlf]], [[1qqd|1qqd]], [[1tmc|1tmc]], [[2clr|2clr]], [[2hla|2hla]], [[3hla|3hla]]</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1gzq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1gzq OCA], [http://www.rcsb.org/pdb/explore.do?structureId=1gzq RCSB], [http://www.ebi.ac.uk/pdbsum/1gzq PDBsum]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1gzq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1gzq OCA], [http://pdbe.org/1gzq PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=1gzq RCSB], [http://www.ebi.ac.uk/pdbsum/1gzq PDBsum]</span></td></tr> | ||
</table> | </table> | ||
== Disease == | == Disease == | ||
Line 29: | Line 29: | ||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
</div> | </div> | ||
<div class="pdbe-citations 1gzq" style="background-color:#fffaf0;"></div> | |||
==See Also== | ==See Also== | ||
Line 36: | Line 37: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Human]] | ||
[[Category: Cerundolo, V]] | [[Category: Cerundolo, V]] | ||
[[Category: Gadola, S D]] | [[Category: Gadola, S D]] |
Revision as of 02:33, 10 September 2015
CD1B IN COMPLEX WITH PHOPHATIDYLINOSITOLCD1B IN COMPLEX WITH PHOPHATIDYLINOSITOL
Structural highlights
Disease[B2MG_HUMAN] Defects in B2M are the cause of hypercatabolic hypoproteinemia (HYCATHYP) [MIM:241600]. Affected individuals show marked reduction in serum concentrations of immunoglobulin and albumin, probably due to rapid degradation.[1] Note=Beta-2-microglobulin may adopt the fibrillar configuration of amyloid in certain pathologic states. The capacity to assemble into amyloid fibrils is concentration dependent. Persistently high beta(2)-microglobulin serum levels lead to amyloidosis in patients on long-term hemodialysis.[2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Function[B2MG_HUMAN] Component of the class I major histocompatibility complex (MHC). Involved in the presentation of peptide antigens to the immune system. Evolutionary Conservation![]() Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf. Publication Abstract from PubMedThe human genome encodes five nonpolymorphic major histocompatibility complex class I-like glycoproteins, CD1a to CD1e, that present lipid antigens for specific recognition by T lymphocytes. Using single alkyl chain detergents, we developed a protocol to generate recombinant human CD1b-lipid complexes. We present here the crystal structures of CD1b in complex with either phosphatidylinositol or ganglioside GM2 at 2.3 A and 2.8 A resolutions, respectively. The antigen-binding groove houses four interlinked hydrophobic channels that are occupied by the alkyl chains of the glycolipid plus two detergent molecules. A distinct exit beneath the alpha 2 helix further contributes to the plasticity of the binding groove. These structures reveal the mechanism by which two alkyl chain lipids bind to CD1b, and how CD1b can adapt to ligands of different alkyl chain length. They also suggest how very long alkyl chains, such as those of mycolic acid, could be fully contained within the binding groove. These results extend the spectrum of potential CD1b ligands by revealing that, in addition to two alkyl chain lipids, mono-alkyl and triple-alkyl chain lipids can be accommodated in the binding groove. Structure of human CD1b with bound ligands at 2.3 A, a maze for alkyl chains.,Gadola SD, Zaccai NR, Harlos K, Shepherd D, Castro-Palomino JC, Ritter G, Schmidt RR, Jones EY, Cerundolo V Nat Immunol. 2002 Aug;3(8):721-6. Epub 2002 Jul 15. PMID:12118248[15] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
|